A Phase 2/3 interventional study of Niclosamide and Placebo in COVID-19, sponsored by NeuroBo Pharmaceuticals Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by NeuroBo Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 823rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 70 in phase 2/3, and was the 758th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
NeuroBo Pharmaceuticals Inc. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
NeuroBo Pharmaceuticals Inc. has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study of ANA001 in Moderate and Severe COVID-19 Patients
This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe hospitalized COVID-19 patients compared to placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Evidence of critical illness, defined by at least 1 of the following:
Respiratory failure requiring at least 1 of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Drug: Niclosamide
Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
Drug: Placebo
Niclosamide is an antihelmintic with in-vitro antiviral activity
Also known as: ANA001
Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Also known as: Matching Placebo to ANA001
Number of Subjects Experiencing TEAEs
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Randomization to Day 60
Number of Subjects Experiencing TESAEs
Incidence of Treatment Emergent Serious Adverse Events (TESAEs)
Time frame: Randomization to Day 60
Median Time to Hospital Discharge
Median time until patient is discharged from hospital. Discharge is defined as a score of 1 or 2 in the WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death".
Time frame: Randomization to Day 60
Median Time to 2-point Improvement WHO Clinical Improvement Scale
Median Time to 2-point Improvement in WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death"
Time frame: Randomization to Day 60
Median Time to Resolution of COVID-19 Symptoms
Median time (in days) to resolution of subjective symptoms assessed by the Investigator to be potentially due to COVID-19 including: fever, cough (productive or non-productive), sore throat, malaise, headache, muscle pain, gastrointestinal symptoms (i.e., nausea, vomiting, or diarrhea), shortness of breath (with or without exertion), and respiratory distress
Time frame: Randomization to Day 60
Median Time to Time-to-Viral Load Undetectable
Median number of days to viral load undetectable by nasopharyngeal (NP) swab
Time frame: Randomization to Day 60
AUC 0-t (h*ng/mL)
Area under the drug concentration (h\*ng/mL) (AUC) vs time curve on Days 1 and 2
Time frame: Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.
Cmax (ng/mL)
Maximum post dose plasma drug concentration on \[Cmax (ng/mL)\] Days 1 and 2
Time frame: Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.
Tmax (h)
Time to maximum post dose plasma drug concentration on \[Tmax (h)\] Days 1 and 2
Time frame: Pre- dose (within 30mins prior to each dose) and 1, 4 and 8 hours after each dose.
| Milestone | ANA001 | Matching Placebo |
|---|---|---|
| Started | 25 | 24 |
| Subjects dosed | 23 | 23 |
| Completed | 15 | 15 |
| Not completed | 10 | 9 |
| Withdrew: Not dosed | 2 | 1 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Adverse event | 2 | 2 |
Incidence of Treatment Emergent Adverse Events (TEAEs)
| Participants | ANA001 | Matching Placebo |
|---|---|---|
| No. of Subjects with any TEAE | 16 | 12 |
| No. of Subjects with Mild (Grade 1) TEAEs | 9 | 2 |
| No. of Subjects with Moderate (Grade 2) TEAEs | 5 | 4 |
| No. of Subjects with Severe (Grade 3) TEAEs | 0 | 2 |
| No. of Subjects with Life-Threatening (Grade 4) TEAEs | 0 | 1 |
| No. of Subjects with Death (Grade 5) TEAEs | 2 | 3 |
Incidence of Treatment Emergent Serious Adverse Events (TESAEs)
| Participants | ANA001 | Matching Placebo |
|---|---|---|
| Number of Subjects Experiencing TESAEs | 3 | 6 |
Median time until patient is discharged from hospital. Discharge is defined as a score of 1 or 2 in the WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death".
| Days | ANA001 | Matching Placebo |
|---|---|---|
| Median Time to Hospital Discharge | 6.03 (3.07 to 14.89) | 13.92 (5.85 to NA) |
Median Time to 2-point Improvement in WHO Ordinal Scale for Clinical Improvement. This is a 9 point ordinal scale with 0 indicating "No clinical or virological evidence of infection" and 8 indicating "Death"
| Days | ANA001 | Matching Placebo |
|---|---|---|
| Median Time to 2-point Improvement WHO Clinical Improvement Scale | 4.15 (2.98 to 6.96) | 13.91 (5.85 to NA) |
Median time (in days) to resolution of subjective symptoms assessed by the Investigator to be potentially due to COVID-19 including: fever, cough (productive or non-productive), sore throat, malaise, headache, muscle pain, gastrointestinal symptoms (i.e., nausea, vomiting, or diarrhea), shortness of breath (with or without exertion), and respiratory distress
| Days | ANA001 | Matching Placebo |
|---|---|---|
| Median Time to Resolution of COVID-19 Symptoms | 17 (9 to 36) | 16 (11 to 24) |
Median number of days to viral load undetectable by nasopharyngeal (NP) swab
| Days | ANA001 | Matching Placebo |
|---|---|---|
| Median Time to Time-to-Viral Load Undetectable | 13.09 (2.87 to 27.04) | 13.1 (2.99 to 15.10) |
Area under the drug concentration (h\*ng/mL) (AUC) vs time curve on Days 1 and 2
| h*ng/mL | ANA001 |
|---|---|
| Day 1: AUC 0-t (h*ng/mL) | 1728.6 ± 1410.21 |
| Day 2: AUC 0-t (h*ng/mL) | 2839.0 ± 1702.25 |
Maximum post dose plasma drug concentration on \[Cmax (ng/mL)\] Days 1 and 2
| ng/mL | ANA001 |
|---|---|
| Day 1: Cmax (ng/mL) | 348.06 ± 212.343 |
| Day 2: Cmax (ng/mL) | 435.91 ± 204.059 |
Time to maximum post dose plasma drug concentration on \[Tmax (h)\] Days 1 and 2
| (h) | ANA001 |
|---|---|
| Day 1: Tmax (h) | 4.884 ± 2.3139 |
| Day 2: Tmax (h) | 3.983 ± 2.4002 |
Collected over TEAEs are any adverse events that emerge on or after first dosing and up to 28 days after last dose during follow-up.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ANA001 | 2/22 (9.1%) | 3/22 (13.6%) | 16/22 (72.7%) |
| Matching Placebo | 3/23 (13%) | 6/23 (26.1%) | 12/23 (52.2%) |
| Event | ANA001 | Matching Placebo |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/22 | 4/23 |
| Septic shockInfections and infestations | 1/22 | 3/23 |
| SepsisInfections and infestations | 1/22 | 0/23 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/22 | 0/23 |
| DizzinessNervous system disorders | 1/22 | 0/23 |
| AnxietyPsychiatric disorders | 1/22 | 0/23 |
| Renal tubular necrosisRenal and urinary disorders | 1/22 | 0/23 |
| Deep vein thrombosisVascular disorders | 1/22 | 0/23 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/22 | 1/23 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/22 | 1/23 |
| Event | ANA001 | Matching Placebo |
|---|---|---|
| InsomniaPsychiatric disorders | 1/22 | 5/23 |
| AnxietyPsychiatric disorders | 2/22 | 3/23 |
| ConstipationGastrointestinal disorders | 1/22 | 3/23 |
| NauseaGastrointestinal disorders | 2/22 | 1/23 |
| DiarrhoeaGastrointestinal disorders | 2/22 | 0/23 |
| HypocalcaemiaMetabolism and nutrition disorders | 2/22 | 1/23 |
| HypokalaemiaMetabolism and nutrition disorders | 2/22 | 1/23 |
| HyponatraemiaMetabolism and nutrition disorders | 2/22 | 1/23 |
| FallInjury, poisoning and procedural complications | 2/22 | 0/23 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/22 | 2/23 |
| Age, Customized(Participants) | ANA001 | Matching Placebo | Total |
|---|---|---|---|
| 18 -<40 Years | 5 | 3 | 8 |
| 40-<65 Years | 13 | 15 | 28 |
| >/=65 Years | 7 | 6 | 13 |
| Sex: Female, Male(Participants) | ANA001 | Matching Placebo | Total |
|---|---|---|---|
| Female | 13 | 10 | 23 |
| Male | 12 | 14 | 26 |
| Ethnicity (NIH/OMB)(Participants) | ANA001 | Matching Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 12 |
| Not Hispanic or Latino | 17 | 18 | 35 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | ANA001 | Matching Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 7 |
| White | 20 | 18 | 38 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Days from First COVID-19 Symptom to Randomisation(Days) | ANA001 | Matching Placebo | Total |
|---|---|---|---|
| Mean | 7.6 ± 4.12 | 7.7 ± 3.53 | 7.7 ± 3.81 |
| Baseline WHO Ordinal Scale for Clinical Improvement(Participants) | ANA001 | Matching Placebo | Total |
|---|---|---|---|
| Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement= 4 | 3 | 4 | 7 |
| Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement = 5 | 19 | 17 | 36 |
| Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement = 6 | 1 | 2 | 3 |
| Baseline World Health Organisation (WHO) Ordinal Scale for Clinical Improvement = Missing | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Feb 2022, 16 months.
Results were first posted in May 2025, 3 years 2 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 16 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niclosamide
NeuroBo Pharmaceuticals Inc.